Press Releases July 16, 2026 08:00 AM

Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

Integra LifeSciences to report Q2 2026 earnings and host conference call on July 29, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences Holdings Corporation announced it will release its second quarter 2026 financial results before market open on July 29, 2026. The company's management will hold a conference call and live webcast to discuss the results, emphasizing their role as a global medical technology leader specializing in neurosurgery and tissue reconstruction.

Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Integra LifeSciences will release Q2 2026 earnings on July 29, 2026, prior to market open.
  • A conference call and live webcast will be held at 8:30 AM ET to discuss the results.
  • The company focuses on advanced medical technologies in neurosurgery and tissue reconstruction, impacting the healthcare sector.

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. 

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

Integra LifeSciences Holdings Corporation


Risks

  • Financial results may not meet investor expectations, potentially affecting stock price.
  • The medical technology sector is subject to regulatory and reimbursement challenges.
  • Market competition and operational risks could impact future performance.

More from Press Releases

ServisFirst Bancshares, Inc. Declares Third Quarter Cash Dividend Sep 21, 2026 Pricing of CNH Industrial Capital Canada Ltd. Cdn$200 million notes due 2028 and Cdn$350 million notes due 2030 Sep 21, 2026 BOSS Zhipin Reports Accelerated Second-Quarter Growth and Strengthened Shareholder Returns Sep 21, 2026 Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit Sep 21, 2026 Brookfield Corporation Announces Pricing of $600 Million Notes Due 2031 Sep 21, 2026